GLPG

Galapagos NV American Depositary Receipt (GLPG) | Rumor.io

Galapagos NV

GLPG

Attention (50-day avg)0%

Attention rank (50-day avg)#3,787

Bullish sentiment (50-day avg)100%

Price to earnings ratio3.18

Market capitalization2B

Earnings per share8.71

Dividend yield (TTM)—

Revenue (annual)1.1B

Net income (annual)320.9M

Social

What share of all stock conversation is about GLPG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 24

Galapagos N.V. ($GLPG) is in talks with Gilead Sciences ($GILD) to form a strategic collaboration following Gilead's acquisition of Ouro Medicines for up to $2.18 billion.
The partnership would involve Galapagos covering 50% of the upfront costs and 50% of the contingent value rights (CVR) for the acquired assets, potentially reshaping the economics of the deal.
Galapagos stands to benefit from the partnership, with the potential for better financial terms and a new purpose for its T-cell engager assets.

Generated by AI

Sentiment

Of the messages about GLPG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	72.22% -2.64
Bearish	—	—	—	27.78% +2.64

Bullish· Jan 28

$GLPG is expected to reach $50 in the near future, driven by a new talented executive and positive market sentiment.
The company's new CEO, commercial products, large development pipeline, and strong cash position make it an attractive investment opportunity.
$GLPG has shown a strong uptrend, with a 23.23% quarterly gain, and is currently in an uptrend, with a positive MACD Histogram and increased volume.

Bearish· Jul 15

Galapagos' research lab lacks drugs, making it a biotech with no substance.
The company's recent deal with Gilead may be the worst in recent years, and its management has a poor track record in research and development.
The market believes Galapagos will waste money on bad launches, research disasters, and expensive deals, resulting in a historic negative EV and a downward trend.

Generated by AI

Topics

Of the messages about GLPG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0.47%
Announcements	—	—	—	51.02%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	48.5%

Analysts· Jan 19

Morgan Stanley upgraded Galapagos to "Overweight" with a price target of $129, citing attractive entry-point after recent pullback and market underestimating risks associated with filgotinib's Euro launch.
The analyst believes Galapagos' management will be disciplined with expenses, and current cash of €5.30B is greater than the market cap.
Morgan Stanley's upgrade is based on the company's pipeline opportunities, including its partnership with Gilead, which is seen as a key driver of growth.

Announcements· Mar 24

Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.18 billion, with Galapagos participating in the deal and co-developing a key asset.
Galapagos will cover 50% of the upfront payment and 50% of the contingent value rights (CVR) to retain 20-23% of the rights and royalties from the acquired asset.
The deal is expected to reshape the economics of the asset and may lead to a sector rotation, with Galapagos potentially benefiting from better financial terms.

Generated by AI

Community

Of the messages about GLPG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	86.38%
Newcomers	—	—	100%	13.62%

Regulars· May 13

Galapagos is walking back its plan to spin off its cell therapy unit, which has raised questions about the viability of this asset class and the company's ability to unlock shareholder value.
The company's decision to keep the cell therapy unit, despite having a significant cash reserve, may have been influenced by Belgian labor laws and the need to reduce headcount, which could have been a barrier to selling the unit.
Some regulars are speculating about a potential buyout or merger between Galapagos and another company, possibly Adaptimmune, which could be facilitated by the activist investors in both companies.

Newcomers· Jan 28

New CEO, Henri Stoffels, will lead Galapagos' rebound as its new chief executive.
Galapagos' weekly candle is showing a strong performance, with some investors looking to get in on the stock.
The new CEO's appointment has sparked both positive and negative reactions from investors, with some questioning the decision.

Generated by AI

News

Lakefront Biotherapeutics director resigns for Sanofi role

2mo agoInvesting.com

Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley

2mo agoInvesting.com

Lakefront draws Equal Weight rating at Morgan Stanley (LKFT)

2mo agoSeeking Alpha

Also Discussed

Investors talking about GLPG also mention

#	Name	Attention
1	argenx SE American Depositary ReceiptARGX	0%0
2	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01
3	Gilead Sciences, Inc.GILD	0%-0.04
4	Cellectis S.A. ADRCLLS	0%0
5	GNFT - Genfit S.A.	——
6	Vertex Pharmaceuticals Incorporated Common StockVRTX	0%-0.01
7	MRUS - Merus N.V.	——
8	Incyte Corp.INCY	0%new
9	Novartis AG Sponsored ADRNVS	0%-0.01
10	SGEN - Seagen Inc.	——

Galapagos NV American Depositary Receipt

Healthcare
Biotechnology

Galapagos NV American Depositary Receipt represents shares in Galapagos NV, a fully integrated biotechnology company headquartered in Mechelen, Belgium, and founded in 1999. The company focuses on transforming patient outcomes through life-changing science and innovation in immunology and oncology. It develops best-in-class therapies using multiple drug modalities, including small molecules, biologicals, and advanced cell therapies such as CAR-T products manufactured via a decentralized, point-of-care platform for rapid vein-to-vein delivery. Key therapeutic areas encompass immunology indications like rheumatoid arthritis, ulcerative colitis, axial spondyloarthritis, dermatomyositis, and systemic lupus erythematosus, alongside oncology programs targeting non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Galapagos synergizes internal expertise with external partnerships to accelerate discovery, development, and delivery of innovative medicines addressing high unmet medical needs. With operations spanning Europe and the United States, it maintains a deep pipeline and collaborates with leading organizations to pioneer next-generation treatments for serious diseases.

Website

Location

Generaal De Wittelaan L11 A3

Mechelen, 2800

Belgium

Social

What share of all stock conversation is about GLPG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 24

Galapagos N.V. ($GLPG) is in talks with Gilead Sciences ($GILD) to form a strategic collaboration following Gilead's acquisition of Ouro Medicines for up to $2.18 billion.
The partnership would involve Galapagos covering 50% of the upfront costs and 50% of the contingent value rights (CVR) for the acquired assets, potentially reshaping the economics of the deal.
Galapagos stands to benefit from the partnership, with the potential for better financial terms and a new purpose for its T-cell engager assets.

Generated by AI

Sentiment

Of the messages about GLPG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	72.22% -2.64
Bearish	—	—	—	27.78% +2.64

Bullish· Jan 28

$GLPG is expected to reach $50 in the near future, driven by a new talented executive and positive market sentiment.
The company's new CEO, commercial products, large development pipeline, and strong cash position make it an attractive investment opportunity.
$GLPG has shown a strong uptrend, with a 23.23% quarterly gain, and is currently in an uptrend, with a positive MACD Histogram and increased volume.

Bearish· Jul 15

Galapagos' research lab lacks drugs, making it a biotech with no substance.
The company's recent deal with Gilead may be the worst in recent years, and its management has a poor track record in research and development.
The market believes Galapagos will waste money on bad launches, research disasters, and expensive deals, resulting in a historic negative EV and a downward trend.

Generated by AI

Topics

Of the messages about GLPG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0.47%
Announcements	—	—	—	51.02%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	48.5%

Analysts· Jan 19

Morgan Stanley upgraded Galapagos to "Overweight" with a price target of $129, citing attractive entry-point after recent pullback and market underestimating risks associated with filgotinib's Euro launch.
The analyst believes Galapagos' management will be disciplined with expenses, and current cash of €5.30B is greater than the market cap.
Morgan Stanley's upgrade is based on the company's pipeline opportunities, including its partnership with Gilead, which is seen as a key driver of growth.

Announcements· Mar 24

Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.18 billion, with Galapagos participating in the deal and co-developing a key asset.
Galapagos will cover 50% of the upfront payment and 50% of the contingent value rights (CVR) to retain 20-23% of the rights and royalties from the acquired asset.
The deal is expected to reshape the economics of the asset and may lead to a sector rotation, with Galapagos potentially benefiting from better financial terms.

Generated by AI

Community

Of the messages about GLPG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	86.38%
Newcomers	—	—	100%	13.62%

Regulars· May 13

Galapagos is walking back its plan to spin off its cell therapy unit, which has raised questions about the viability of this asset class and the company's ability to unlock shareholder value.
The company's decision to keep the cell therapy unit, despite having a significant cash reserve, may have been influenced by Belgian labor laws and the need to reduce headcount, which could have been a barrier to selling the unit.
Some regulars are speculating about a potential buyout or merger between Galapagos and another company, possibly Adaptimmune, which could be facilitated by the activist investors in both companies.

Newcomers· Jan 28

New CEO, Henri Stoffels, will lead Galapagos' rebound as its new chief executive.
Galapagos' weekly candle is showing a strong performance, with some investors looking to get in on the stock.
The new CEO's appointment has sparked both positive and negative reactions from investors, with some questioning the decision.

Generated by AI

Galapagos NV

Social

Mar 24

Bullish· Jan 28

Bearish· Jul 15

Analysts· Jan 19

Announcements· Mar 24

Regulars· May 13

Newcomers· Jan 28

Lakefront Biotherapeutics director resigns for Sanofi role

Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley

Lakefront draws Equal Weight rating at Morgan Stanley (LKFT)

Also Discussed

Galapagos NV American Depositary Receipt

Company Information

Location

Lakefront Biotherapeutics director resigns for Sanofi role

Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley

Lakefront draws Equal Weight rating at Morgan Stanley (LKFT)

Also Discussed

Social

Mar 24

Bullish· Jan 28

Bearish· Jul 15

Analysts· Jan 19

Announcements· Mar 24

Regulars· May 13

Newcomers· Jan 28